Table 5.

Changes in IGF-1 concentrations and different tests` scores after vortioxetine treatment

	At baseline n = 48	After treatment n = 48	Mean change	p
Psychopathological symptoms
MADRS total score	29 (22–33)	6 (3–11)	20.8	< 0.0001
CGI-S score	4 (4–5)	1 (1–2)	2.3	< 0.0001
Patient-reported cognitive symptoms
PDQ-5 total score	7 (4–10)	2 (1–3)	4.7	< 0.0001
Performance-based cognition
RAVLT immediate recall	51 (43–55)	68 (64–72)	−15.9	< 0.0001
TMT-B (s)	75 (63–96)	47 (36–60)	30.1	< 0.0001
DSST	54 (42–61)	62 (51–71)	−9.7	< 0.0001
IGF-1 level (ng/ml)	236 (184–316)	170 (132–210)	89.0	< 0.0001

Data are presented as median (upper-lower quartile); p according to Wilcoxon test (paired samples)